Interpreting the Results

Making the active surveillance decision for very low, low-, and favorable intermediate-risk patients

The Oncotype DX GPS report for clinically lower risk patients provides actionable data that predicts tumor aggressiveness to help guide the critical treatment decision between active surveillance and immediate treatment.^1-4

Deciding on treatment modality for unfavorable intermediate- and high-risk patients

Interactive report guide

Quickly and easily understand how to interpret the Genomic Prostate Score report, and view sample reports .

Getting your results

Most Oncotype DX GPS results are available within two weeks of the date the specimen is received at the Exact Sciences Laboratory. You can access the results through the online physician portal  or receive the report by fax.

View Sample Reports

PLACEHOLDER  Download High-Risk Sample Report

 Download Favorable Intermediate NCCN risk and a GPS result of 12 Report

 Download Unfavorable Intermediate NCCN risk and a GPS result of 20 Report

 Download Low NCCN risk and a GPS result of 10 Report

 Download Low NCCN risk and a GPS result of 58 Report

Report Highlights
Compare Report Results

Start Report Guide

Overall Risk

How does the overall clinical picture look?
By combining the Oncotype DX Genomic Prostate Score® (GPS) result with clinical features, the report provides clear risk stratification.

Prognosis*

What do long-term outcomes look like?
The Oncotype DX Genomic Prostate Score® has been prospectively validated to independently predict 10-year clinical risk of prostate cancer death and metastasis.

*From the KPNC clinical validation study, in which all patients received radical prostatectomy.

Tumor aggressiveness*

How aggressive is the underlying biology?
This single number is the most immediate and clinically actionable endpoint, predicting the patient's likelihood of adverse pathology (Gleason ≥ 4+3 and/or pT3+).

*From the UCSF and CPDR clinical validation studies.

Clinical utility

In this example, the patient's clinical features are consistent with NCCN Low Risk. Utilization of the GPS Test™ enables reclassification to NCCN Very Low Risk.

Start Report Guide

GPS distribution*

How does your patient's GPS result compare to his pre-test risk group?
Helps to personalize your conversations for shared decision-making about treatment options.

*From the KPNC, UCSF and CPDR clinical validation studies.

Pathology endpoints*

What is the risk for disease progression?
Get your patient's individualized risks for high grade disease and non-organ-confined disease.

*From a meta-analysis of the UCSF and CPDR clinical validation studies..

Page 1 2

Download PDF

Start Report Guide

NCCN Risk Group*

Here we have two patients whose clinical features categorize them as NCCN Low Risk

*National Comprehensive Cancer Network® clinical practice guidelines for prostate cancer.

GPS+NCCN Risk Group*

After the GPS test, one patient was downgraded to very low risk, while the other was upgraded to unfavorable intermediate or high risk.

The GPS result can help you determine which patient would benefit from Active Surveillance vs. immediate treatment.

*National Comprehensive Cancer Network® clinical practice guidelines for prostate cancer.

Start Report Guide

GPS Distribution*

On the back page of the report, you can see how the GPS results for these two patients compare to results from other men in the same pre-test risk group (NCCN Low).

*From the KPNC, UCSF and CPDR clinical validation studies.

Page 1 2